Thomas Mercier

Thomas Mercier

Auto-generated profile, based on publicly available information

Thomas Mercier

Laboratory & Service of Medical Pharmacology, Department of Laboratory Medicine and Pathology, and Department of Medicine, University Hospital of Lausanne and University of Lausanne, Switzerland

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2010 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
LDLaurent Arthur Decosterd
Laurent Arthur Decosterd
BRBertrand Rochat
Bertrand Rochat
BPBenoît Pesse
Benoît Pesse
TMThomas Mercier
Thomas Mercier
FTFrédÉrIc Tissot
FrédÉrIc Tissot
OMOscar Marchetti
Oscar Marchetti
Therapeutic drug monitoring (TDM) may contribute to optimizing the efficacy and safety of antifungal therapy because of the large variability in drug pharmacokinetics. Rapid, sensitive, and selective laboratory methods are needed for efficient TDM. Quantification of several antifungals in a single analytical run may best fulfill these requirements. We therefore developed a multiplex ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method requiring 100 μl of plasma for simultaneous quantification within 7 min of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole- N -oxide, caspofungin, and anidulafungin. Protein precipitation with acetonitrile was used in a single extraction procedure for eight analytes. After reverse-phase chromatographic separation, antifungals were quantified by electrospray ionization-triple-quadrupole mass spectrometry by selected reaction monitoring detection using the positive mode. Deuterated isotopic compounds of azole antifungals were used as internal standards. The method was validated based on FDA recommendations, including assessment of extraction yields, matrix effect variability (<9.2%), and analytical recovery (80.1 to 107%). The method is sensitive (lower limits of azole quantification, 0.01 to 0.1 μg/ml; those of echinocandin quantification, 0.06 to 0.1 μg/ml), accurate (intra- and interassay biases of −9.9 to +5% and −4.0 to +8.8%, respectively), and precise (intra- and interassay coefficients of variation of 1.2 to 11.1% and 1.2 to 8.9%, respectively) over clinical concentration ranges (upper limits of quantification, 5 to 50 μg/ml). Thus, we developed a simple, rapid, and robust multiplex UPLC-MS/MS assay for simultaneous quantification of plasma concentrations of six antifungals and two metabolites. This offers, by optimized and cost-effective lab resource utilization, an efficient tool for daily routine TDM aimed at maximizing the real-time efficacy and safety of different recommended single-drug antifungal regimens and combination salvage therapies, as well as a tool for clinical research.

1 April 2009 in Journal of Chromatography B
Verified
Journal Article
Closed access
Eva Maria HodelEva Maria Hodel
Eva Maria Hodel
BZB. Zanolari
B. Zanolari
TMT. Mercier
T. Mercier
JBJ. Biollaz
J. Biollaz
JKJ. Keiser
J. Keiser
LDLaurent Arthur Decosterd
Laurent Arthur Decosterd

19 November 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
EGElinam Gayi
Elinam Gayi
LNLaurence Neff
Laurence Neff
XMXènia Massana Muñoz
Xènia Massana Muñoz
HHHesham M Ismail HAMED
Hesham M Ismail HAMED
MSMarta Sierra
Marta Sierra
LSLeonardo Scapozza
Leonardo Scapozza
X-linked myotubular myopathy (XLMTM, also known as XLCNM) is a severe congenital muscular disorder due to mutations in the myotubularin gene, MTM1. It is characterized by generalized hypotonia, leading to neonatal death of most patients. No specific treatment exists. Here, we show that tamoxifen, a well-known drug used against breast cancer, rescues the phenotype of Mtm1-deficient mice. Tamoxifen increases lifespan several-fold while improving overall motor function and preventing disease progression including lower limb paralysis. Tamoxifen corrects functional, histological and molecular hallmarks of XLMTM, with improved force output, myonuclei positioning, myofibrillar structure, triad number, and excitation-contraction coupling. Tamoxifen normalizes the expression level of the XLMTM disease modifiers DNM2 and PI3KC2B, likely contributing to the phenotypic rescue. Our findings demonstrate that tamoxifen is a promising candidate for clinical evaluation in XLMTM patients.

1 August 2014 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
DMDominic Mosha
Dominic Mosha
Monia GuidiMonia Guidi
Monia Guidi
FMFelista Mwingira
Felista Mwingira
SASalim Abdulla
Salim Abdulla
TMThomas Mercier
Thomas Mercier
BGBlaise Genton
Blaise Genton
Artemether-lumefantrine (AL) is the first-line treatment for uncomplicated malaria in the second and third trimesters of pregnancy. Its efficacy during pregnancy has recently been challenged due to altered pharmacokinetic (PK) properties in this vulnerable group. The aim of this study was to determine the PK profile of AL in pregnant and nonpregnant women and assess their therapeutic outcome. Thirty-three pregnant women and 22 nonpregnant women with malaria were treated with AL (80/480 mg) twice daily for 3 days. All patients provided five venous plasma samples for drug quantification at random times over 7 days. Inter- and intraindividual variability was assessed, and the effects of covariates were quantified using a nonlinear mixed-effects modeling approach (NONMEM). A one-compartment model with first-order absorption and elimination with linear metabolism from drug to metabolite fitted the data best for both arthemether (AM) and lumefantrine (LF) and their metabolites. Pregnancy status and diarrhea showed a significant influence on LF PK. The relative bioavailability of lumefantrine and its metabolism rate into desmethyl-lumefantrine were, respectively, 34% lower and 78% higher in pregnant women than in nonpregnant patients. The overall PCR-uncorrected treatment failure rates were 18% in pregnant women and 5% in nonpregnant women (odds ratio [OR] = 4.04; P value of 0.22). A high median day 7 lumefantrine concentration was significantly associated with adequate clinical and parasitological response ( P = 0.03). The observed reduction in the relative bioavailability of lumefantrine in pregnant women may explain the higher treatment failure in this group, mostly due to lower posttreatment prophylaxis. Hence, a modified treatment regimen of malaria in pregnancy should be considered.

11 February 2019 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
Frederic Michel LamothFrederic Michel Lamoth
Frederic Michel Lamoth
TMT Mercier
T Mercier
PAP André
P André
JPJ L Pagani
J L Pagani
OPO Pantet
O Pantet
LDLaurent Arthur Decosterd
Laurent Arthur Decosterd

1 April 2018 in Journal of Chromatography B
Verified
Journal Article
Closed access
ECEvelina Cardoso
Evelina Cardoso
TMThomas Mercier
Thomas Mercier
AWAnna Dorothea Wagner
Anna Dorothea Wagner
KHKrisztian Homicsko
Krisztian Homicsko
OMOlivier Michielin
Olivier Michielin
LDLaurent Arthur Decosterd
Laurent Arthur Decosterd